Eleven Biotherapeutics (EBIO) Misses Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St futures rise as AI stocks catch their breath; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts EBIO Hot Sheet
Join SI Premium – FREE
Eleven Biotherapeutics (NASDAQ: EBIO) reported Q3 EPS of ($0.50), $0.17 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $68 thousand versus the consensus estimate of $100 thousand.
For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Public Service Enterprise (PEG) Misses Q3 EPS by 4c ; Offers Guidance
- TAT Technologies (TATT) Tops Q3 EPS by 18c
- Tower Semiconductor (TSEM) Misses Q3 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
